These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 29783477)

  • 1. The use of the 'linked evidence approach' to guide policy on the reimbursement of personalized medicines.
    Merlin T
    Per Med; 2014 Jun; 11(4):435-448. PubMed ID: 29783477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing personalized medicines in Australia: a national framework for reviewing codependent technologies.
    Merlin T; Farah C; Schubert C; Mitchell A; Hiller JE; Ryan P
    Med Decis Making; 2013 Apr; 33(3):333-42. PubMed ID: 22895559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The "linked evidence approach" to assess medical tests: a critical analysis.
    Merlin T; Lehman S; Hiller JE; Ryan P
    Int J Technol Assess Health Care; 2013 Jul; 29(3):343-50. PubMed ID: 23769128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group.
    Faulkner E; Annemans L; Garrison L; Helfand M; Holtorf AP; Hornberger J; Hughes D; Li T; Malone D; Payne K; Siebert U; Towse A; Veenstra D; Watkins J;
    Value Health; 2012 Dec; 15(8):1162-71. PubMed ID: 23244820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the "Linked Evidence Approach" Method on Policies to Publicly Fund Diagnostic, Staging, and Screening Medical Tests.
    Merlin TL; Hiller JE; Ryan P
    MDM Policy Pract; 2016; 1(1):2381468316672465. PubMed ID: 30288408
    [No Abstract]   [Full Text] [Related]  

  • 6. Payers and the assessment of clinical utility for companion diagnostics.
    Quinn B
    Clin Pharmacol Ther; 2010 Dec; 88(6):751-4. PubMed ID: 21081944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United States.
    Frueh FW
    Value Health; 2013; 16(6 Suppl):S27-31. PubMed ID: 24034309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating personalized genomic medicine into routine clinical care: addressing the social and policy issues of pharmacogenomic testing.
    Dressler LG
    N C Med J; 2013; 74(6):509-13. PubMed ID: 24316779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized medicine and the role of health economics and outcomes research: issues, applications, emerging trends, and future research.
    O'Donnell JC
    Value Health; 2013; 16(6 Suppl):S1-3. PubMed ID: 24034305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Health Technology Assessment of companion diagnostics: experience of NICE.
    Byron SK; Crabb N; George E; Marlow M; Newland A
    Clin Cancer Res; 2014 Mar; 20(6):1469-76. PubMed ID: 24634470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using companion and coupled diagnostics within strategy to personalize targeted medicines.
    Singer DR; Watkins J
    Per Med; 2012 Sep; 9(7):751-761. PubMed ID: 29776269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalized medicine policy challenges: measuring clinical utility at point of care.
    van Rooij T; Wilson DM; Marsh S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):289-95. PubMed ID: 22812553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment in Australia: a role for clinical registries?
    Scott AM
    Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
    Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
    Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.